Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus vs. tacrolimus in de novo kidney transplant recipients
NCT00261820Phase 4Completed
- Sponsor
- Pfizer
- Modality
- Small Molecules
01
Overview
Phase 4, randomised trial of sirolimus in graft rejection (2 arms), sponsored by Pfizer. Primary endpoint: Graft function as measured by Glomerular Filtration Rate (GFR) by Nankivell formula at 12 months. Status: completed.
02
Drugs
sirolimus
03
Conditions
graft rejection
Beyond the preview
Go deeper on NCT00261820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261820.